Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Accounts Payables (2020 - 2025)

Historic Accounts Payables for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to $1.6 million.

  • Gain Therapeutics' Accounts Payables rose 4545.45% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 4545.45%. This contributed to the annual value of $946259.0 for FY2024, which is 2825.75% down from last year.
  • Latest data reveals that Gain Therapeutics reported Accounts Payables of $1.6 million as of Q3 2025, which was up 4545.45% from $2.7 million recorded in Q2 2025.
  • Gain Therapeutics' 5-year Accounts Payables high stood at $2.7 million for Q2 2025, and its period low was $560479.0 during Q4 2021.
  • Its 5-year average for Accounts Payables is $1.4 million, with a median of $1.3 million in 2023.
  • Per our database at Business Quant, Gain Therapeutics' Accounts Payables tumbled by 4170.88% in 2021 and then skyrocketed by 19012.68% in 2022.
  • Gain Therapeutics' Accounts Payables (Quarter) stood at $560479.0 in 2021, then soared by 190.13% to $1.6 million in 2022, then decreased by 18.89% to $1.3 million in 2023, then dropped by 28.26% to $946259.0 in 2024, then surged by 69.09% to $1.6 million in 2025.
  • Its Accounts Payables stands at $1.6 million for Q3 2025, versus $2.7 million for Q2 2025 and $2.2 million for Q1 2025.